COMMUNIQUÉS West-GlobeNewswire

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
03/09/2026
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
ANI Pharmaceuticals to Present at September Investor Conferences
03/09/2026
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the [...]
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
03/09/2026
ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with [...]
Biodesix to Participate in Upcoming Investor Conferences
03/09/2026
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming [...]
Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026
03/09/2026
Revenue increase driven by significant growth in the United States and other strategic markets NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “ [...]
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
03/09/2026
University of Szeged installed Hungary’s first Robotic Magnetic Navigation system in July Over 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globally Robotics enabled [...]
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
03/09/2026
Repurchase reduces unsecured note balance to approximately $364.7 million Management to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03, 2026 ( [...]
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
03/09/2026
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” [...]
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
03/09/2026
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious [...]
Crescent Biopharma to Present at September Investor Conferences
03/09/2026
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
03/09/2026
SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Trevi Therapeutics to Participate in Upcoming September Conferences
03/09/2026
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
03/09/2026
- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates [...]
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
03/09/2026
Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ET NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and [...]
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
03/09/2026
MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Amwell® receives Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for addressing healthcare fragmentation
03/09/2026
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of technology enabled care, has received Frost & Sullivan's 2026 United States Technology Innovation Leadership Recognition in the [...]
Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials
03/09/2026
Cette acquisition apporte au réseau de développement clinique précoce de Fortrea des compétences bioanalytiques dédiées et une capacité accrue alors que Worldwide poursuit sa stratégie visant à renforcer ses activités [...]
Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026
03/09/2026
SHANGHAI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, announced today that its “AI + Chronic Care” [...]
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
03/09/2026
Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly [...]

Pages